DC
ADPT icon

Diametric Capital’s Adaptive Biotechnologies ADPT Stock Holding History

Diametric Capital’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-209,438
Closed -$1.49M – 303
2022
Q3 		$1.49M Buy
209,438
+32,316
+18% +$304K 0.75% 30
2022
Q2 		$1.43M Sell
177,122
-87,878
-33% -$773K 1.06% 15
2022
Q1 		$3.68M Buy
+265,000
New +$4.17M 2.03% 5

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
BWLSA
Blue Water Life Science Advisors Larkspur, California $125M AUM 91.82% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Diametric Capital's ADPT Position: Q4 2022 in Review

Diametric Capital sold out of Adaptive Biotechnologies (ADPT) in Q4 2022, closing a stake of 209,438 shares — an estimated $1.49M sold.

Diametric Capital first reported a position in ADPT in Q1 2022 and held it in 3 quarters. The position peaked at $3.68M in Q1 2022. 223 funds tracked by Wall St. Rank hold ADPT as of Q4 2022.

  • Diametric Capital reported no remaining Adaptive Biotechnologies position as of Q4 2022 after selling out during the quarter.
  • Diametric Capital sold 209,438 Adaptive Biotechnologies shares in Q4 2022, an estimated $1.49M.
  • Diametric Capital first reported a position in Adaptive Biotechnologies in Q1 2022 and held it in 3 quarters.
  • Diametric Capital's Adaptive Biotechnologies position peaked at $3.68M in Q1 2022.
  • 223 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q4 2022.

Based on Diametric Capital's 13F filing for Q4 2022, filed 29 Mar 2023.